Modality
Radioligand
MOA
CD47i
Target
JAK2
Pathway
Epigenetic
Crohn'sFLGIST
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
May 2022
→ Dec 2025
Phase 2Current
NCT06379474
2,033 pts·FL
2022-05→2025-12·Recruiting
2,033 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-12-024mo agoPh3 Readout· FL
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P2/3
Recruit…
Catalysts
Ph3 Readout
2025-12-02 · 4mo ago
FL
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06379474 | Phase 2/3 | FL | Recruiting | 2033 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |